Exact Sciences Corp (EXAS) Misses Q1 Expectations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Exact Sciences (EXAS) Spec Buy Reiterated at Benchmark; Co. Anything But Revenue and Earnings Story
May 1, 2014 2:57 PM EDTBenchmark maintained a Speculative Buy rating on Exact Sciences (NASDAQ: EXAS) with a price target of $25.00. Comments follow Q1 results.
"Revenues were $0.3 Million and EPS was ($0.23). That being said, Exact Sciences is anything but a revenue and earnings storyat least for now. The company made significant progress on two fronts. The publication of the results of the DEEP-C Study in the New England Journal of Medicine highlighted what the benefits of the... More
